September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Secondary analysis of a prospective, phase II RCT for metastatic HNSCC – Memorial Sloan Kettering Radiation Oncology
Jun 7, 2024, 20:40

Secondary analysis of a prospective, phase II RCT for metastatic HNSCC – Memorial Sloan Kettering Radiation Oncology

Memorial Sloan Kettering Radiation Oncology shared on X:

“New from Drs James Janopaul-Naylor and Sean McBride:.

This secondary analysis of a prospective, phase II RCT for metastatic HNSCC (nivolumab +/− SBRT) found no significant impacts on efficacy and toxicity of treatment time-of-day/circadian rhythm.”.

Source: Memorial Sloan Kettering Radiation Oncology/X